English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18034/20233 (89%)
造訪人次 : 23354899      線上人數 : 468
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/32502


    標題: Erythropoietin prevents dementia in hemodialysis patients: a nationwide population-based study
    作者: Hung, Peir-Haur
    Yeh, Chih-Ching
    Sung, Fung-Chang
    Hsiao, Chih-Yen
    Muo, Chih-Hsin
    Hung, Kuan-Yu
    Tsai, Kuen-Jer
    貢獻者: Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Internal Med
    Chia Nan Univ Pharm & Sci, Dept Appl Life Sci & Hlth
    Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth
    China Med Univ, Dept Publ Hlth
    China Med Univ Hosp, Management Off Hlth Data
    China Med Univ, Coll Med, Sch Med, Grad Inst Clin Med Sci
    Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Internal Med
    Natl Cheng Kung Univ, Coll Med, Inst Clin Med
    Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Ctr Clin Med
    關鍵字: Alzheimer's disease
    erythropoietin
    end-stage renal disease
    hemodialysis
    日期: 2019
    上傳時間: 2020-07-29 13:47:36 (UTC+8)
    出版者: IMPACT JOURNALS LLC
    摘要: Erythropoietic medications such as including erythropoietin (EPO) are known to be neuroprotective and to correlate with improved cognitive functions. However, it is not known whether supplementation with EPO reduces the risk of dementia in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). Here, we determined whether EPO levels correlate with the incidence of different dementia subtypes, including Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia (UnD), and whether such associations vary with annual cumulatively defined daily doses (DDDs) of EPO for ESRD patients receiving HD. This retrospective study included data from 43,906 adult ESRD patients who received HD between 1999 and 2010. Using hazard ratios and Cox regression models, we found that patients receiving EPO had a 39% lower risk of general dementia than those in the non-EPO group. Similarly, the risks of VaD and UnD was lower for patients in the EPO cohort. The risk of dementia was further reduced in HD patients treated with EPO in combination with iron. Our results suggest that the use of EPO medications in HD patients is associated with a reduced risk of VaD and UnD, but not AD, regardless of whether EPO is used alone or in combination with iron.
    關聯: Aging-Us, v.11, n.17, pp.
    顯示於類別:[生活保健科技系] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML965檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋